Laurenz J C, Hadjisavas M, Schuster D, Bazer F W
Department of Animal Science, Texas A&M University, College Station 77843-2471, USA.
Comp Biochem Physiol B Biochem Mol Biol. 1997 Nov;118(3):579-86. doi: 10.1016/s0305-0491(97)00225-3.
The present study investigated the effect of uteroferrin and recombinant bovine granulocyte-monocyte/macrophage colony stimulating factor (rbGM-CSF) on hematopoiesis in young female pigs. Uteroferrin (100 micrograms/kg in 0.9% NaCl), rbGM-CSF (10 micrograms/kg in 0.9% NaCl), uteroferrin + rbGM-CSF (as above), or control (0.9% NaCl) were administered as intramuscular injections twice daily (0800 and 2000 hr). Peripheral blood cell number, composition, and progenitor cells were determined over 28 days. Uteroferrin had minimal effects on white blood cell (WBC) number, while rbGM-CSF caused both a rapid (days 2-7; maximum 122 +/- 8% of baseline) and late (days 16-28; maximum 133 +/- 8% of baseline) increase in WBC. Combination treatment with uteroferrin + rbGM-CSF abolished the initial increase in WBC number,but resulted in a prolonged increase in WBC number (days 14-28) relative to control. The rbGM-CSF-induced increase in WBC number resulted from rapid increases (P < 0.05) in monocytes and neutrophils. The addition of uteroferrin + rbGM-CSF enhanced (P < 0.05) the initial increase in the monocyte population and augmented the neutrophilia. In addition, uteroferrin + rbGM-CSF resulted in a dramatic eosinophilia (days 2-28), which was not detected in either the uteroferrin or rbGM-CSF treatments. Although not substantially affected by uteroferrin alone, rbGM-CSF caused an increase (P < 0.05) in thrombocyte numbers from days 1 through 9 (maximum 133 +/- 11% of baseline), an effect augmented by cotreatment with uteroferrin. The ability of these cytokines to modulate blood cell number and composition appeared to result from their effects on hematopoietic progenitor cells. Treatment of pigs with uteroferrin increased (P < 0.05) CFU-GEMM, CFU-GM, and BFU-E progenitor cells in peripheral blood, while rbGM-CSF caused increases (P < 0.05) relative to control in CFU-GM and CFU-GEMM. These effects were additive, as uteroferrin + GM-CSF augmented the increases in CFU-GM, BFU-E, and CFU-GEMM. Collectively, these results indicate that uteroferrin and rbGM-CSF can modulate hematopoiesis in young pigs. These effects were both additive and, in the case of neutrophils and eosinophils, synergistic. Hence, the mechanism(s) by which uteroferrin and rbGM-CSF modulate hematopoiesis appear to be different.
本研究调查了子宫铁蛋白和重组牛粒细胞-单核细胞/巨噬细胞集落刺激因子(rbGM-CSF)对幼年雌性猪造血功能的影响。子宫铁蛋白(100微克/千克,溶于0.9%氯化钠溶液)、rbGM-CSF(10微克/千克,溶于0.9%氯化钠溶液)、子宫铁蛋白+rbGM-CSF(如上所述)或对照(0.9%氯化钠溶液)通过肌肉注射给药,每日两次(08:00和20:00)。在28天内测定外周血细胞数量、组成和祖细胞。子宫铁蛋白对白细胞(WBC)数量影响极小,而rbGM-CSF导致WBC迅速增加(第2 - 7天;最高达到基线的122±8%)和后期增加(第16 - 28天;最高达到基线的133±8%)。子宫铁蛋白+rbGM-CSF联合治疗消除了WBC数量的初始增加,但相对于对照导致WBC数量延长增加(第14 - 28天)。rbGM-CSF诱导的WBC数量增加是由于单核细胞和中性粒细胞迅速增加(P < 0.05)。添加子宫铁蛋白+rbGM-CSF增强了(P < 0.05)单核细胞群体的初始增加并增强了嗜中性粒细胞增多。此外,子宫铁蛋白+rbGM-CSF导致显著的嗜酸性粒细胞增多(第2 - 28天),这在子宫铁蛋白或rbGM-CSF治疗中均未检测到。虽然单独的子宫铁蛋白对其影响不大,但rbGM-CSF从第1天到第9天导致血小板数量增加(P < 0.05)(最高达到基线的133±11%),子宫铁蛋白联合治疗增强了这一效应。这些细胞因子调节血细胞数量和组成的能力似乎源于它们对造血祖细胞的作用。用子宫铁蛋白治疗猪增加了(P < 0.05)外周血中CFU-GEMM、CFU-GM和BFU-E祖细胞,而rbGM-CSF相对于对照使CFU-GM和CFU-GEMM增加(P < 0.05)。这些效应是相加的,因为子宫铁蛋白+GM-CSF增强了CFU-GM、BFU-E和CFU-GEMM的增加。总体而言,这些结果表明子宫铁蛋白和rbGM-CSF可以调节幼年猪的造血功能。这些效应既是相加的,对于中性粒细胞和嗜酸性粒细胞而言,也是协同的。因此,子宫铁蛋白和rbGM-CSF调节造血功能的机制似乎不同。